All In Biotech

Drug Trial Radar · NCT02627196

Baroreflex Activation Therapy for Heart Failure

Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,090 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,090

Actual

Start

Apr 19, 2016

Primary completion

Oct 2023

Study completion Oct 2023

Sponsor

Lead sponsor
CVRx, Inc.Industry
Sponsor type
Industry
First posted
Dec 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III, left ventricular ejection fraction (LVEF) ≤ 35% and NT-proBNP\<1600 pg/ml despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT). The total trial duration is anticipated to be approximately 5 years; however, the duration of an individual subject enrollment will depend on when he or she entered the trial.

Conditions

  • Heart Failure

Interventions

  • BAROSTIM NEO® SystemDevice

  • Medical ManagementDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Cardiovascular Mortality and Heart Failure MorbidityTime frame: From randomization until data-cut date for the endpoint analysis. Median follow-up was 3.6 years per patient.
  2. Major Adverse Neurological and Cardiovascular Events (MANCE)Time frame: 6 months post implant
  3. Percent Change in Log 10 Amino-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) From Baseline to 6 Months Post-implantTime frame: 6 months post-implant
  4. Change to Six Minute Hall Walk (6MHW)Time frame: Baseline and 6 months post-implant
  5. Change in Minnesota Living With Heart Failure Quality of Life (MLWHF QOL) ScoreTime frame: Baseline and 6 months post-implant

Locations

92 sites in 2 countries. Site status is shown where the registry gives one.

  • Heart and Rhythm Solutions, PLLC

    Chandler, Arizona

  • Chan Heart Rhythm Institute

    Mesa, Arizona

  • Arizona Arrhythmia Research Center

    Phoenix, Arizona

  • Phoenix Cardiovascular Research Group

    Phoenix, Arizona

  • Cardiovascular Consultants, Ltd.

    Phoenix, Arizona

  • Washington Regional Medical Center

    Fayetteville, Arkansas

  • Central Cardiology Medical Center

    Bakersfield, California

  • Chula Vista Cardiac Center

    Chula Vista, California

  • Sharp Grossmont

    Chula Vista, California

  • Sharp Chula Vista Medical Center

    Chula Vista, California

  • John Muir Health Clinical Research Center

    Concord, California

  • University of California, San Francisco - Fresno

    Fresno, California

  • Herndon Surgery Center

    Fresno, California

  • Glendale Adventist Medical Center

    Glendale, California

  • Memorial Health Services

    Laguna Hills, California

  • Los Alamitos Cardiovascular

    Los Alamitos, California

  • Southern California Permanente Medical Group

    Los Angeles, California

  • University of Southern California

    Los Angeles, California

  • Advanced Cardiovascular Specialists

    Mountain View, California

  • Hoag Memorial Hospital

    Newport Beach, California

  • UC Irvine Health

    Orange, California

  • Desert Heart Regional Medical Center

    Palm Springs, California

  • Huntington Hospital

    Pasadena, California

  • Dignity Health

    Sacramento, California

  • University of California San Francisco

    San Francisco, California

  • Bonometti, Inc

    Santa Barbara, California

  • Adventist Heart Institute

    St. Helena, California

  • North Colorado Medical Center

    Greeley, Colorado

  • Medical Center of the Rockies Research

    Loveland, Colorado

  • Atlantic Clinical Research Center - Cardiology

    Atlantis, Florida

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • Memorial Cardiovascular Institute

    Hollywood, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Avanza Medical Research Center

    Pensacola, Florida

  • University of South Florida

    Tampa, Florida

  • Mercer University

    Macon, Georgia

  • WellStar Medical Group

    Marietta, Georgia

  • St. Alphonsus Medical Center

    Boise, Idaho

  • NorthShore University Health System

    Evanston, Illinois

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.